ADCT
ADC Therapeutics: A Year of Substantial Progress and Exciting Milestones
ADC Therapeutics recently reported its fourth quarter and full-year 2025 financial results, providing an update on the company's achievements in 2025 and its excitement for the future. The company has implemented a strategic plan to focus on ZYNLONTA with optimized lifecycle management, which includes advancing LOTIS-5 as well